Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Total Current Liabilities: 2017-2024

Historic Total Current Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $59.7 million.

  • Crinetics Pharmaceuticals' Total Current Liabilities rose 38.45% to $74.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 38.45%. This contributed to the annual value of $59.7 million for FY2024, which is 35.82% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Total Current Liabilities of $59.7 million as of FY2024, which was up 35.82% from $43.9 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Total Current Liabilities ranged from a high of $59.7 million in FY2024 and a low of $10.5 million during FY2020.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Total Current Liabilities value was $43.9 million (recorded in 2023), while the average stood at $43.8 million.
  • Data for Crinetics Pharmaceuticals' Total Current Liabilities shows a peak YoY spiked of 73.32% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Total Current Liabilities stood at $10.5 million in 2020, then surged by 52.49% to $16.0 million in 2021, then spiked by 73.32% to $27.7 million in 2022, then surged by 58.50% to $43.9 million in 2023, then surged by 35.82% to $59.7 million in 2024.